Pengujian Toksisitas Teratogenik Sediaan Kombinasi Ekstrak Ikan Gabus, Temulawak, dan Meniran pada Tikus

Abstract

Background: Pregnant women are one of the groups most vulnerable to nutritional problems. These problems includeanemia and chronic energy deficiency (CHD). Pregnant women are usually difficult to find effective drugs to consume when pregnant. Concerns arise when having to consume medicines derived from chemicals, so many pregnant women choose to use traditional medicines. Teratogenic means the abnormal development of cells during pregnancy that causes damage to the embryo so that the formation of organs takes place incompletely (birth defects occur). Objective: The purpose of this study was to determine the ketoxic potential of a combination of cork fish extract, meniran, and temulawak in pregnant rats. Methods: the research method uses 25 pregnant female rats and is divided into five treatment groups where the group is divided into 5 control groups treated with CMC-Na 0.5%, 5 EIGTM treatment groups at a dose of 100 mg / kgbb, 5 EIGTM treatment groups at a dose of 300 mg / kgbb, 5 treatment groups at a dose of 1000 mg / kgbb and the last 5 positive control groups given gabapentin 50 mg / kgbb. Pregnant rats were treated during the organogenesis period starting from day 6 to day 15. On day 19 the mother rat was dissected and the fetus was removed from the uterus to make observations. Observations included reproductive appearance, external malformations and skeletal malformations. The data obtained were then analyzed statistically to see whether the data were normal or not. Results: The results showed that the positive control of gabapentin 50 mg/kgbb and EIGTM doses of 300 mg/kgbb and 1000 mg/kgbb experienced a decrease in maternal weight, fetal weight loss, and fetal length compared to the normal control of CMC-Na of 0.5%. Malformations in the form of humpback body were found in the 1000mg/kgbb dose group and gabapentin positive control 50 mg/kgbb. At the EIGTM dose of 1000 mg/kgbb, the fetus experienced resorption of 3.84% and at the positive control dose of gabapentin 50 mg/kgbb, the fetus experienced resorption of 4%. Fetuses with skeletal malformations were found at EIGTM doses of 300, 1000 mg/kgbb and at gabapentin positive control 50 mg/kgbb.